30
CARDIOVASCULAR
hamburger
Omnilink Elite™ Vascular Balloon-Expandable Stent System
Ordering Information
Absolute Pro Vascular

Elite engineering and performance.

Strength and flexibility that provides superb results in the iliacs.

Engineering

  • Cobalt chromium multi-link technology that allows for thin struts without sacrificing strength for flexibility and vessel conformability
  • Superb accuracy with no stent shortening^
  • Thin struts* to minimize vessel wall injury1
  • Dual-layer balloon for a low profile system to treat difficult-to-reach lesions

Clinical Results

  • 97.0% clinically driven freedom from TLR at 9 months
  • 91.9% patency in TASC C lesions at 2 years in iliacs2*
  • 84.8% patency in TASC D lesions at 2 years in iliacs2**

High Freedom from Clinically-Driven TLR through 3 Years

Event-Free Survival through 3 Years

Significant Improvement in Walking Capacity as Measured by WIQ

WIQ Mean Score
Stent Loop
 

Compliance

NOMINAL AND RATED BURST PRESSURES

Compliance Chart
Stent Close-up

Stent Sizes and Specifications

Stent Sizes and Specifications

Data on file at Abbott unless otherwise noted.

^-1.81% shortening for 8.0 mm x 38 mm size.
*Combined clinical results from BRAVISSIMO study where 66%/34% of TASC C lesions were treated with Absolute Pro™ Vascular Self-Expanding Stent System / Omnilink Elite™ Vascular Balloon-Expandable Stent System respectively.
**Combined clinical results from BRAVISSIMO study where 54%/46% of TASC D lesions were treated with Absolute Pro™ Vascular Self-Expanding Stent System / Omnilink Elite™ Vascular Balloon-Expandable Stent System respectively.
^^Compatible with sheath inner diameters of 2.15 and 2.20 mm for 9 mm x 39 mm, 59 mm and 10 mm x 19 mm, 29 mm, 39 mm stents, respectively.
Omnilink Elite™ PERIPHERAL Vascular Balloon-Expandable Stent System Instructions For Use (IFU). Refer to IFU for additional information.

References

  1. Pache, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. JACC 2003; 41:1283-8.
  2. Donato, G. et al. 24-Month Data from the BRAVISSIMO: A Large-Scale Prospective Registry on Iliac Stenting for TASC A & B and TASC C & D Lesions. Annals of Vascular Surgery. 2015; 29(4): 738-750.

MAT-2116360 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.